--- title: "Lexeo Therapeutics (LXEO) news: offering" url: "https://aibio.space/companies/lexeo-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LXEO offering news: Lexeo Therapeutics files $300 million shelf registration. Lexeo Therapeutics, Inc. (NASDAQ: LXEO), United States." --- LXEO Lexeo Therapeutics, Inc. NASDAQ · United States # Lexeo Therapeutics (LXEO) news LXEO offering news Financings · 2026-10-29 ## [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced. ## Latest Lexeo Therapeutics news 1. 2026-09-29 Mergers [Lexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock](https://aibio.space/news/lexeo-completes-mantle-therapeutics-deal-5-300-000-cash-plus-3-000-000/) Lexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed. 2. 2025-10-17 Financings [Lexeo Therapeutics prices public offering at $8.00 a share, plus $10 million private placement](https://aibio.space/news/lexeo-therapeutics-prices-public-offering-8-00-share-plus-10-million/) Lexeo agrees to sell 15,625,000 shares for expected gross proceeds of approximately $125 million. A concurrent private placement of pre-funded warrants is expected to bring approximately $10 million. 3. 2025-05-27 Financings [Lexeo Therapeutics agrees to $80 million private placement of stock and warrants](https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-stock-warrants/) Lexeo Therapeutics agreed to a private placement of 20,790,120 shares and pre-funded warrants for 6,963,556 more, with common warrants attached, for gross proceeds the company expects to be about $80 million. Part of that figure depends on warrants that have not been exercised, and the runway it cites depends on a 2027 readout. 4. 2025-05-27 Financings [Lexeo Therapeutics agrees to $80 million private placement at $2.8825 per share](https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-2-8825-share/) Lexeo expects gross proceeds of approximately $80 million from 20,790,120 shares or pre-funded warrants at $2.8825, with common warrants struck at $2.82. ## Lexeo Therapeutics at a glance - **Ticker**: LXEO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $211.7 million ### Related companies - [LadRx](https://aibio.space/companies/ladrx/) OTC: LADX - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR - [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) NASDAQ: FENC - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO ### Also on NASDAQ - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NEUP - [LENSAR](https://aibio.space/companies/lensar/) LNSR - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Innovative Eyewear](https://aibio.space/companies/innovative-eyewear/) LUCY - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) AVBP - [Microbot Medical](https://aibio.space/companies/microbot-medical/) MBOT ## Lexeo Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$63.8 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | [$74.1 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | | Net income (loss) | [-$100.0 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | [-$98.3 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | | Cash from operations | [-$98.6 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | [-$81.2 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | | Cash and equivalents | [$63.0 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/) | [$35.0 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/) | | Short-term investments | [$118.8 million](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/) | [$86.5 million](https://www.sec.gov/Archives/edgar/data/1907108/000095017025068536/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $92.8 million, plus short-term investments of $118.9 million, $211.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lexeo Therapeutics Has Lexeo Therapeutics raised money recently? Our latest story on this, dated Oct 29, 2026: "Lexeo Therapeutics files $300 million shelf registration". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/). What is the ticker symbol of Lexeo Therapeutics? Lexeo Therapeutics, Inc. trades under the ticker LXEO on NASDAQ. Where is Lexeo Therapeutics listed? Lexeo Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Lexeo Therapeutics? The SEC Central Index Key (CIK) for Lexeo Therapeutics, Inc. is 1907108. Its filings are on SEC EDGAR. How many shares does Lexeo Therapeutics have outstanding? 82,046,255 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Lexeo Therapeutics listed under? Our directory records Lexeo Therapeutics, Inc. under United States. What does Lexeo Therapeutics do? Our directory classifies Lexeo Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Lexeo Therapeutics? The ISIN recorded for Lexeo Therapeutics, Inc. is US52886X1072. Does aibio.space cover Lexeo Therapeutics? aibio.space lists Lexeo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Lexeo Therapeutics profitable? Lexeo Therapeutics, Inc. reported a net loss of $100.0 million for the fiscal year ended Dec 31, 2025, and used $98.6 million of cash in operations, per its annual report to the SEC. How much does Lexeo Therapeutics spend on research and development? $63.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Lexeo Therapeutics have? $211.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Lexeo Therapeutics (LXEO) stock news? Our latest story on Lexeo Therapeutics, dated Oct 29, 2026: "Lexeo Therapeutics files $300 million shelf registration". Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced. [Source](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/). How long will Lexeo Therapeutics's cash last? From our story of May 27, 2025: The press release headline says the cash runway extends into 2028, and that the proceeds will fund operations through a potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy. [Source](https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-stock-warrants/). Is Lexeo Therapeutics being acquired or merging? Our latest merger story, dated Sep 29, 2026: "Lexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock". Lexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed. [Source](https://aibio.space/news/lexeo-completes-mantle-therapeutics-deal-5-300-000-cash-plus-3-000-000/). ## Investor discussion: Lexeo Therapeutics Members talk about Lexeo Therapeutics (LXEO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lexeo Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-29 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312526437001/d238747ds3.htm) 2. 2026-09-29 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312526407555/lxeo-20260929.htm) 3. 2026-09-22 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-ex99_1.htm) 4. 2025-11-05 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312525265934/d36960ds3.htm) 5. 2025-10-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312525241560/d18447d424b5.htm) 6. 2025-06-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312525140744/d50311ds3.htm) 7. 2025-05-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-ex99_1.htm) 8. 2025-03-24 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312525060883/d876923d424b5.htm) 9. 2024-12-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1907108/000119312524277929/d775189ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LXEO on TradingView](https://www.tradingview.com/symbols/NASDAQ-LXEO/). ## SEC filings and registration - **SEC name**: Lexeo Therapeutics, Inc. - **CIK**: 1907108 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: LXEO (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 345 PARK AVENUE SOUTH, NEW YORK, NY, 10010 - **Phone**: (212) 547-9879 - **Shares outstanding**: 82,046,255 as of 2026-08-10 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526407555/lxeo-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-20260916.htm) filed 2026-09-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/lxeo-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526288703/lxeo-20260625.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-20260615.htm) filed 2026-06-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1907108/000119312526215678/lxeo-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-20260511.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001907108), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lexeo Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LXEO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lexeo Therapeutics, Inc. - **Ticker**: LXEO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US52886X1072 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LXEO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lexeo-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lexeo Therapeutics (LXEO) news: offering", 2026-10-31, https://aibio.space/companies/lexeo-therapeutics/